INTRODUÇÃO:Pacientes em ventilação mecânica (VM) são freqüentemente submetidos ao uso prolongado e/ou a doses elevadas de opióides, que durante a retirada podem causar abstinência dificultando o desmame da VM. Objetivo: testar a hipótese de que a introdução da metadona enteral na fase de desmame da sedação e analgesia em pacientes adultos graves sob VM diminui o tempo de desmame da VM. MÉTODOS: Estudo prospectivo, randomizado, controlado e duplo-cego, realizado entre abril de 2005 e outubro de 2009, em quatro Unidades de Terapia Intensiva (UTIs) de adultos de Joinville, SC. Foram randomizados 75 pacientes que apresentavam critérios para desmame da VM e estavam em uso de fentanil por mais de cinco dias consecutivos ou infusão ³ 5 g/kg/h por 12 horas. Os pacientes foram randomizados em dois grupos: Grupo Metadona (GM) e Grupo Controle (GC). Nas primeiras 24 horas após a inclusão os dois grupos receberam 80% da dose original do fentanil. Ao GM administrou-se metadona via enteral (10 mg cada 6 horas), e ao GC administrou-se placebo via enteral. Após as primeiras 24 horas acrescentou-se infusão intravenosa de solução salina (placebo) no GM, enquanto o GC recebeu infusão de solução intravenosa de fentanil. Em ambos os grupos, a solução venosa foi reduzida em 20% a cada 24 horas. Episódios de intolerância à retirada de opióide foram medicados com suplementação de opióide. Os grupos foram comparados entre si avaliando-se o tempo de desmame da VM, tempo de VM, permanência na UTI e permanência hospitalar. RESULTADOS: Dos 75 pacientes randomizados, sete foram excluídos e 68 foram analisados: 37 no GM e 31 no GC. Entre o início do desmame e a extubação, observou-se maior probabilidade de antecipação da extubação no GM, porém a diferença não foi significativa (Hazard Ratio: 1,52 (IC 95% 0,87 a 2,64; p = 0,11). Analisando-se o intervalo entre a randomização e o quinto dia do desmame da VM, a probabilidade de sucesso de desmame foi significativamente maior no GM (Hazard Ratio: 2,64 (IC 95%: 1,22 a 5,69; p < 0,02). Dentre os 54 pacientes que completaram o desmame da VM (29 do GM e 25 do GC), o tempo de desmame da VM foi significativamente menor no GM (Hazard Ratio: 2.06; IC 95% 1.17 a 3.63; p < 0.004). Não houve diferença entre os grupos com relação ao tempo de VM, permanência na UTI e permanência hospitalar. CONCLUSÃO: a introdução da metadona enteral na fase de desmame da sedação e analgesia de pacientes adultos graves sob VM resultou na diminuição do tempo de desmame da VM / INTRODUCTION: Patients on mechanical ventilation (MV) are often subjected to prolonged use and / or high doses of opioids, which when removed can cause withdrawal syndrome and to difficult weaning from MV. Objective: to test the hypothesis that the introduction of enteral methadone in weaning from sedation and analgesia in critically ill adult patients on MV decreases the time of weaning from MV. METHODS: Prospective, randomized, controlled, double-blind trial, conducted between April 2005 and October 2009 in ICUs of four hospitals in Joinville, SC. We randomized 75 patients who met the criteria for weaning from MV and were using fentanyl for more than 5 consecutive days or infusion ³ 5 g/ kg / h for 12 hours. Patients were randomized into two groups: Methadone group (MG) and Control Group (CG). At first 24 hours both groups received 80% of the original dose of fentanyl and received, additionally, enteral methadone (10mg qid) or enteral placebo. After the first 24 hours, MG: received enteral methadone (10mg qid) and intravenous placebo. CG received enteral placebo and intravenous fentanyl. In both groups, the blinded intravenous solutions were reduced by 20% of the original dose, every 24 hours. Episodes of intolerance opioid withdrawal were treated with supplemental opioid. The groups were compared by evaluating the time of weaning from MV, duration of MV, ICU and hospital stay.RESULTS: Of 75 randomized patients, 7 were excluded and 68 were analyzed: 37 at MG and 31 in CG. Between the beggining of weaning and extubation, there was a greater probability of anticipation of extubation in the MG, but the difference was not significant. (Hazard Ratio: 1,52 (IC 95% 0,87 a 2,64; p = 0,11). Analyzing the interval between randomization and the fifth day of weaning from MV, the probability of successful weaning was significantly higher in GM (Hazard Ratio: 2,64 (IC 95%: 1,22 a 5,69; p < 0,02). Within the 54 patients who completed the weaning from MV (29 on the MG and 25 on the CG), weaning time from MV was significantly less in the MG (Hazard Ratio: 2.06; IC 95% 1.17 a 3.63; p < 0.004). There was no difference between the two groups with respect the duration of MV, length of ICU stay and hospital stay. CONCLUSÃO: the introduction of enteral methadone in weaning from sedation and analgesia of critically ill adult patients on MV decreased the time of weaning from MV

Submitted by Marco Antonio Oliveira da Silva (maosilva@ipen.br) on 2016-12-21T18:09:44Z No. of bitstreams: 0 / Made available in DSpace on 2016-12-21T18:09:44Z (GMT). No. of bitstreams: 0 / A Austrália é um país cuja fauna é um repositório de potenciais novos biofármacos, pois se encontram no continente os animais mais mortais do planeta, dentre eles, as serpentes. A serpente Pseudechis australis (Mulga snake) é a maior serpente venenosa da Austrália e tem ampla distribuição geográfica. Os venenos de serpentes são complexas misturas com proteínas e peptídeos que apresentam uma variedade de atividades biológicas. Devido à riqueza de seus componentes, várias moléculas encontradas no veneno vêm sendo utilizadas com fins terapêuticos, como agentes anticoagulantes ou analgésicos. Apesar dessas informações, existem poucos dados disponíveis sobre os componentes específicos deste veneno. O presente trabalho tem como objetivo isolar e caracterizar as proteases desse veneno, ainda não descritas, um primeiro passo para compreender o papel destas enzimas no processo de envenenamento, assim como seus inibidores endógenos. Estes desempenham uma função protetora da glândula de veneno, inibindo a ação das enzimas in loco, prevenindo assim a degradação do tecido glandular por estas toxinas. O interesse nestes inibidores está relacionado ao seu potencial uso na terapia de diversas doenças como distúrbios da coagulação, hipertensão e câncer. / Dissertação (Mestrado em Tecnologia Nuclear) / IPEN/D / Instituto de Pesquisas Energéticas e Nucleares - IPEN-CNEN/SP

Submitted by Edineia Teixeira (edineia.teixeira@unioeste.br) on 2018-10-08T16:27:39Z No. of bitstreams: 2 Camila_Alpini_2018.pdf: 897809 bytes, checksum: 188fdf141d2f5b2e51f5b8c3bcaf2bad (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-10-08T16:27:39Z (GMT). No. of bitstreams: 2 Camila_Alpini_2018.pdf: 897809 bytes, checksum: 188fdf141d2f5b2e51f5b8c3bcaf2bad (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2018-03-16 / Background: Administrating intraoral drugs alone was not able to reduce the TS after bleaching; the objective of this study was to determine if an association of two drugs could induce analgesia at a higher level. Methods: A triple-blind, parallel-randomized clinical trial was conducted with 115 patients receiving either an association of ketorolac tromethamine 10mg /acetaminophen 750mg or a placebo. The first dose was administered 1h before the in-office bleaching, and extra doses every 8h for 48h. The TS was recorded on VAS (0-10) and NRS (0-4) scales, during bleaching and1-6h, 12-18h, 18-24h, 24-48h post-bleaching. The color was measured before and one month after dental bleaching using two visual shade guide and spectrophotometer. The absolute risk of TS was evaluated by Chi-square test. The TS intensity for both scales were compared with ANOVA tests and Mann-Whitney U test. Comparisons between times within each group were performed by the Friedman test. The color changes between groups were compared by the Student t-test (α = 0.05). Results: No significant differences in the absolute risk of TS and color between the groups (p > 0.05), however the intensity of TS decreased in the experimental group for the periods 12 to 24h (p > 0.04) and 24 to 48 h (p > 0.03). Conclusion: The ketorolac tromethamine/acetaminophen association prior to in-office bleaching does not reduce the risk, but reduce the intensity of TS after 12h. Practical Implications: Using two analgesics was capable to prevent TS arising from in-office dental bleaching after 12h. / Introdução: A administração de drogas intra-orais isoladamente não foi capaz de reduzir a SD após o clareamento, o objetivo deste estudo foi determinar se associação de duas drogas pode induzir a analgesia a um nível mais elevado. Metodologia: Um ensaio clínico randomizado, paralelo, triplo-cego foi conduzido com 115 pacientes, os quais receberam uma associação de cetorolaco de trometamina 10mg e paracetamol 750mg ou placebo. A primeira dose administrada 1h antes do clareamento e as doses extras a cada 8h durante 48 h. A SD foi registrada nas escalas: VAS (0-10) e NRS (0-4) em diferentes períodos: durante o clareamento até 1h, 6h, 12h, 24h e 48h pós-clareamento. A cor foi registrada inicialmente e 1 mês após o clareamento, com as escalas visuais e um espectrofotômetro. O risco absoluto foi avaliado pelo teste Qui-quadrado. A intensidade de sensibilidade para ambas as escalas foi realizada pelo teste de ANOVA e Mann-Whitney. Comparações entre os tempos, dentro de cada grupo, foram realizadas pelo teste de Friedman. As alterações de cor entre os grupos foram comparadas pelo teste t de Student (α=0.05). Resultados: Não foram observadas diferenças estatisticamente significantes entre os grupos para o risco de SD e cor, porém intensidade da SD no grupo experimental diminuiu no período de 12 a 24h (p > 0.04) e 24 a 48 h (p > 0.03) após o clareamento (p > 0.05). Conclusão: A associação de paracetamol e toragesic não reduz a prevalência de SD, mas reduz a intensidade de SD após 12h do clareamento de consultório. Relevância clínica: O uso de dois analgésicos foi capaz de diminuir a intensidade de SD decorrente do clareamento de consultório após 12 horas do mesmo.

Abstract Excessive pain after surgery causes many kinds of endocrine, metabolic and inflammatory responses, which may increase postoperative morbidity and mortality - especially among elderly patients. This study evaluated the effect of peripheral and central pain relief techniques after joint surgery. Intravenously administered doses of 100 mg, 200 mg and 300 mg of ketoprofen decreased the requirement for opioid (fentanyl) in a dose-dependent manner by 38%, 45% and 53%, respectively, compared with a placebo, without any noticeable ceiling-effect, when administered after hip and knee arthroplasty. Patients receiving a 300 mg dose of ketoprofen had significantly lower postoperative pain scores than those receiving a placebo. There were no significant differences in incidences of nausea and vomiting, or in the amount of bleeding between the ketoprofen and placebo groups. Intravenous doses of 200 mg of ketoprofen, 150 mg of diclofenac, and 120 mg of ketorolac produced similar postoperative pain scores and requirement for opioid (fentanyl) with no intergroup differences in the incidence of nausea and vomiting and in the amount of bleeding, when administered after hip arthroplasty. The addition of ropivacaine, 1 mg·ml-1, did not decrease the requirement for epidural fentanyl administered via a patient-controlled analgesia device for postoperative pain relief after hip arthroplasty. Both drug infusions provided effective pain relief. The most common adverse effect was pruritus, which occurred in a similar number of patients in both groups. An interscalene brachial plexus block with ropivacaine decreased the dose of PCA-delivered oxycodone by 78% after arthroscopic shoulder surgery while subacromial bursa blockade with ropivacaine decreased it by only 11 % compared to a placebo during the 20 hour study period. Postoperative pain scores were significantly lowest with a interscalene brachial plexus block.

With an increasing prevalence of osteoarthritis, total knee (TKA) and hip (THA) arthroplasty are the second-and third-most common surgeries in Canada. Although these procedures improve pain and function for a majority of patients, some patients report persistent postoperative pain. Opioids are conventionally used for these patients even though they are associated with addiction, falls, overdose, and death. Recently, many strategies have been proposed to decrease reliance on opioids after TKA and THA, including opioid-free and opioid-reduced multimodal protocols for pain management. Our findings demonstrate that Canadian patients’ receptivity to opioid-free or reduced postoperative protocols is associated with their perception of the efficacy and safety of opioids compared to non-opioid alternatives, and current opioid use. More patients are open to opioid-reduced postoperative care as they perceive that pain will be intolerable without opioids. This overlaps with many Canadian surgeons’ perception that opioids cannot be completely eliminated from postoperative pain management regimens and that patients expect an intolerable level of pain after surgery, warranting opioid use. This highlights a need for enhanced patient education on the safety and efficacy of opioids and alternatives, while managing patients’ expectations of postoperative pain control. Most Canadian and Dutch surgeons reported that they prescribe opioids to nearly all of their patients postoperatively. However, our cross-sectional study indicates that 40% of Canadian patients would be open to receiving no opioids postoperatively. In contrast, Japanese surgeons believed that opioids are unnecessary for managing postoperative pain. Variations observed among orthopaedic surgeons in Canada, the Netherlands, and Japan can be attributed to differences at the surgeon-level (individual practices and beliefs), patient-level (patient characteristics and preferences), and system-level (regulatory frameworks and healthcare systems). Further research is required on surgeon-centered approaches to mitigating opioid use, focusing on education and guidelines/policies for opioid prescribing. / Thesis / Master of Science (MSc) / Opioid analgesics are routinely prescribed to manage pain after total knee and hip replacement surgery. However, opioids are not typically more effective than alternatives and are associated with addiction, overdose, and death. This thesis aims to understand the perceptions of patients and orthopaedic surgeons on opioid use after total knee and hip replacement surgery. The findings demonstrate that more patients are open to receiving opioid-reduced surgery compared to opioid-free surgery, with receptivity being associated with patients’ perceptions of opioid efficacy and safety and current opioid use, highlighting a need for improved patient education. Additionally, orthopaedic surgeons identified challenges and facilitators to postoperative opioid reduction in six key areas: opioid prescribing practices, patient factors, collaborative care, policies/guidelines, surgeon education and training, and personal perceptions/beliefs. Compared to Canadian and Dutch surgeons, Japanese surgeons heavily relied on non-opioid medications as they believed that opioids are unnecessary for managing postoperative pain.

No / The purpose of this paper is to present the findings of one part of a larger study, funded by the National Institute for Health Research, which explored the management of pain in adult male prisoners in one large category B prison in England. In this paper, the authors focus on the attitudes and perceptions of prison staff towards pain management in prison. A qualitative design was utilised to explore the staff perceptions of pain and pain management in one adult male prison. Questionnaires were provided for all staff with prisoner contact, and a follow up focus group was undertaken to further explore questionnaire data. The questionnaire and focus group findings demonstrated that staff had a good awareness of pain and pain management in prison, with both physical and emotional pain identified. The frequency of approaches by prisoners to staff for pain relief was noted to be high, whilst awareness of how the prison environment could potentially exacerbate pain was discussed. The acquisition of analgesia by prisoners for secondary gain was identified as a challenge to both assessing levels of pain and providing pain relief in prison, illustrating the complexity of providing care within a custodial culture. The effect on staff of caring for prisoners found to be confrontational and deceitful was significant for participants, with feelings of anger and frustration reported. This study was undertaken in one adult male category B prison with a very high turnover of prisoners. Staff working in other types of prison, for example, higher security or those more stable with longer sentenced prisoners could provide alternative views, as may staff caring for younger offenders and women. The challenges to undertaking research in prison with staff who can understandably be reluctant to engage in reflection on their practice cannot be underestimated and impact significantly on available methodologies. This qualitative research is the first of its kind to offer the perspectives of both health care professionals and prison staff working with prisoners complaining of pain in an English prison. It provides the groundwork for further research and development.

No / The kinetics of the dissociation is fundamental to the formation and the in vivo performance of cyclodextrin supramolecules. The individual determination of the apparent dissociation rate constant (kd,app) using high performance affinity chromatography (HPAC) is a tedious process requiring numerous separate studies and massive data fitting. In this study, the multianalyte approach was employed to simultaneously measure the kd,app values of three drugs through one injection based on the investigation of the dependence of drug-cyclodextrin interaction kinetics on the mobile phase composition. As a result, the kd,app values increased when decreasing the ion strength, increasing the ionization of drugs and adding extra organic solvents. The values of kd,app for acetaminophen, phenacetin and S-flurbiprofen estimated by the multianalyte approach were 8.54+/-1.81, 5.36+/-0.94 and 0.17+/-0.02s(-1), respectively, which were in good agreement with those determined separately (8.31+/-0.58, 5.01+/-0.42 and 0.15+/-0.01s(-1)). For both of the single and multiple flow rate peak profiling methods, the results of the multianalyte approach were statistically equivalent with that of the single compound analysis for all of the three drugs (p>0.05). The multianalyte approach can be employed for the efficient evaluation of the drug-cyclodextrin kinetics with less variance caused by cyclodextrin column bleeding.

The rapid growth in opioid therapy for non-cancer pain has occurred without an adequate appreciation of the consequences of this growth. Few studies provide patient-centered evidence that can be used to inform the current proposed standards for efficacious (safe and effective) opioid prescribing in non-cancer pain. Furthermore, different terms may be used interchangeably in the literature to refer to opioid-taking behaviors, resulting in imprecise or vague interpretation of existing evidence. We therefore sought to explore patterns of opioid-taking behavior and their biopsychosocial-spiritual determinants in African-American adults with sickle cell disease (SCD). Many questions surround opioid use for non-cancer pain, but little has been published about behavioral patterns of taking opioids in these conditions. The main objective of this study was to develop a disease-specific scale for describing prescribed opioid taking in patients with sickle cell disease (SCD). As part of a multiphase, mixed-methods study, we used an adaptation of several published methods to construct 9 sequential, chronological steps for developing a new scale. We report here wide-ranging quantitative and semi-structured, qualitative interviews of 13 male and 11 female African-American adults with SCD, average age 36 years, from various socioeconomic and educational levels. We used grounded theory, priori and posteriori procedures to analyze the qualitative data, and to conduct an appraisal of translational validity. Scale development results have led to inclusion in the draft scale of new concepts namely momentary medication-taking behavior. The scale also captures concrete patterns of adherence for as-needed and scheduled medication and allows for several discovered conceptual domains that explain observed opioid-taking behaviors. These concepts challenge the current theories and models of medication-taking behavior and adherence. In summary, we found that contextual factors may drastically affect opioid-taking behaviors. Together, These uncovered phenomena raise new hypotheses that may challenge current theories and models of medication-taking behaviors and methods of assessing adherence. These hypotheses call for a new round of research on opioid-taking behavior, and need to be rigorously tested in future research

Embora existam muitos estudos clínicos avaliando analgésicos e o controle da dor em cães, poucos são realizados em animais com dor do câncer e submetidos a procedimento cirúrgico para ressecção da neoplasia como a maxilectomia e mandibulectomia. Este estudo clínico foi realizado de forma prospectiva, comparativa, aleatória e de maneira simples cego com o propósito de avaliar a eficácia analgésica de diferentes tratamentos no período pós-operatório em cães submetidos à maxilectomia ou mandibulectomia. Foram utilizados no estudo 42 cães com neoplasia oral. Todos os animais foram prémedicados com acepromazina (0,05mg/kg) associado à meperidina (2mg/kg) por via intramuscular e a anestesia foi induzida com propofol por via iv na dose suficiente realizar a intubação (2.3-6.5mg/kg). O isoflurano foi utilizado para a manutenção da anestesia. Trinta minutos antes do fim do procedimento cirúrgico, os cães foram distribuídos aleatoriamente em um dos 5 diferentes grupos para analgesia pósoperatória: tramadol 2mg/kg (Tra), codeína 2mg/kg (Co), cetoprofeno 2mg/kg (Ce), tramadol 2mg/kg associado ao cetoprofeno 2mg/kg (TraCe) ou codeína 2mg/kg associado ao cetoprofeno 2mg/kg (CoCe), por via subcutânea. A freqüência cardíaca (FC) e respiratória (FR), pressão arterial sistólica (PAS), pressão arterial diastólica (PAD) e pressão arterial média (PAM), glicose sanguínea, cortisol e interleucina-6 (IL- 6) e grau de sedação foram verificados até 24 horas, e grau de analgesia foi verificado por até 120 horas do início da administração do analgésico, ou seja, os respectivos tratamentos foram mantidos por 5 dias da seguinte forma: tramadol ou codeína a cada 8 horas e cetoprofeno a cada 24 horas por via oral (MBL, M1, M2, M3, M4, M5, M24, M48, M72, M96 e M120). O resgate analgésico foi realizado nos animais que apresentaram escore de dor 4 em qualquer momento do estudo (dipirona 25mg/kg e morfina 0,1mg/kg). A análise estatística foi realizada por meio do Kruskal-Wallis, Friedman para mensurações repetidas, ANOVA e teste 2. Os gráficos em boxplot ou diagrama em caixas representam a distribuição dos dados. Os valores com p<0,05 foram considerados significantes. Não houve diferença entre os grupos de tratamento com relação ao peso, tempo de cirurgia, tempo para extubação, FC, FR, PAS, PAD e PAM, cortisol e IL-6 séricos, e escore de dor pela escala de análise descritiva. A concentração da glicose sanguínea aumentou de forma significante com relação aos valores basais no grupo Tra (M5= 96±14), Co (M1= 120±66 e M3=96±21), Ce (M5= 105±22) e CoCe (M3=104±16). Aumento do escore de dor foi observado no M2 do grupo Tra em relação a MBL e M1 a M5 do grupo Co em relação a M120 (p<0,05), contudo a média do escore não foi maior que 2,7. Baixo grau de sedação ainda foi observado no grupo CoCe no M24 (0,1±0,4 p<0,001) com relação ao M1. O número de resgate foi baixo, totalizando 19 administrações. No grupo Ce houve maior necessidade de resgate analgésico. Com base nos resultados obtidos, pôde-se concluir que os grupos de tratamento analgésico promoveram controle da dor pós-operatória de boa qualidade na maioria dos cães do estudo e com baixa incidência de efeitos adversos, podendo ser indicados no controle da dor em procedimentos de maxilectomia e mandibulectomia. / Although there are many clinical studies evaluating analgesics and pain control in dogs, very few were carried out in animals with cancer pain, and submitted to oncologic surgery with tumor resections such as maxillectomy and mandibulectomy. This clinical, prospective, randomized, simple blinded study was performed with the purpose of evaluating analgesic efficacy of different treatments in the postoperative period in dogs submitted to maxillectomy or mandibulectomy. Forty-two client-owned dogs with oral tumor were used in the study. Dogs were premedicated with acepromazine (0.05mg kg-1) and meperidine (2mg kg-1) by the intramuscular route and anesthesia was induced with intravenous propofol in a dose sufficient to allow intubation (2.3-6.5mg-1). Isoflurane was used for maintenance of anesthesia. Thirty minutes prior to the end of surgery, dogs were randomly allocated in one of 5 different groups for postoperative analgesia: tramadol 2mg kg-1 (Tra), codeine 2mg kg-1 (Co), ketoprofen 2mg kg-1 (Ke), tramadol 2mg kg-1 + ketoprofen 2mg kg-1 (TraKe) or codeine 2mg kg-1 + ketoprofen 2mg kg-1 (CoKe), subcutaneously. Heart (HR) and respiratory (RR) rates, systolic (SBP), median (MBP) and diastolic (DBP) blood pressures, blood glucose, serum cortisol and interleukin-6 (IL-6) and degree of sedation were recorded for 24 hours, and degree of analgesia were evaluated until 120 hours of the start of analgesic administration (MBL, M1, M2, M3, M4, M5, M24, M48, M72, M96 and M120), being that treatments were maintained for 5 days as follows: codeine or tramadol every 8 hours and the ketoprofen every 24 hours orally. Analgesic rescue was delivered to animals with pain scores equal or superior to 4 at any time of the study (dypirone 25mg -1 and morphine 0,1mg-1). Statistical analyses were performed by means of the Kruskal-Wallis, Friedmann for repeated measures, ANOVA and 2 tests. Graphics boxplot or box diagrams represents dates of distribution. Values of p<0.05 were considered significant. There were no differences between groups related to weight, surgical time, extubation time, HR, RR, SBP, MBP, DBP, serum cortisol and IL-6, and pain score by Descriptive Scale (DS). Blood glucose concentrations were significantly increased in relation to baseline, in groups Tra (M5= 96±14), Co (M1= 120±66 e M3=96±21), Ke (M5= 105±22) and CoKe (M3=104±16). Increase of pain score was observed in M2 of group Tra in relation to baseline, and M1 to M5 of group Co in relation to M120 (p<0,05), however the average score was not higher than 2.7. Low level of sedation was also observed in group CoKe in M24 (0.1 ± 0.4 - p <0.001) compared to M1.. The number of rescue was low, totaling 19 administrations. Ke group required more analgesic rescue. So, it can be conclude that treatment analgesic groups promoted a good quality pain control of postoperative in most of the dogs in the study and with low incidence of side effects, could be indicated in the control of the pain in procedures of maxillectomy and mandibulectomy.

Abstract not available